Phase 4
Completed N=33
Comparative Efficacy and Safety of Benzoyl Peroxide Used in Combination With Clindamycin vs. Benzoyl Peroxide Used in Combination With Clindamycin and Doxycycline in the Treatment of Moderate Acne
Source: ClinicalTrials.gov NCT00837213 ↗Enrolled (actual)
33
Serious AEs
0.0%
Results posted
Aug 2010
Primary outcomePrimary: Percent Change in Inflammatory Acne Lesions From Baseline to Week 16 — -52.70; -48.84 Percent change
Summary
To compare the efficacy and safety of Benzoyl peroxide used in combination with clindamycin vs. Benzoyl peroxide used in combination with clindamycin and doxycycline in the treatment of moderate acne
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percent Change in Inflammatory Acne Lesions From Baseline to Week 16 |
-52.70; -48.84 | — |
| PRIMARY Percent (%) Change in Non-inflammatory Acne Lesions From Baseline to Week 16. |
-25.27; -44.69 | — |
| PRIMARY Percent Change in Total Acne Lesion Counts From Baseline to Week 16 |
-38.49; -46.11 | — |
| PRIMARY Change in Investigator Global Assessment (IGA) |
-0.42; -0.61; -0.55; -0.85; -1; -1.09 | — |
| SECONDARY Percent (%) Change in Inflammatory Lesion Counts (Chest and Back) From Baseline to Week 12 |
-49.04; -45.44 | — |
| SECONDARY Percent Change in Non-inflammatory Lesions (Chest and Back) From Baseline to Week 12 |
-38.43; -38.52 | — |
| SECONDARY Percent Change in Total Lesions (Chest and Back) From Baseline to Week 12 |
-44.16; -41.74 | — |
| SECONDARY Percentage of Particpants With IGA Score at Week 16 |
0; 8.3; 0; 8.3; 30; 25 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female subjects with acne vulgaris . Able to understand the requirements of the study and sign informed consent/HIPAA authorization forms.
Exclusion Criteria
- Known hypersensitivity to any of the components of the study drugs or used of prohibited medications or any medical condition that contraindicate the subject's participation in the clinical study
Data sourced from ClinicalTrials.gov (NCT00837213). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.